menu
    • menu
    [{"orgOrder":0,"company":"Yiviva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"Sorafenib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Yiviva","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Yiviva \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Yiviva \/ Not Applicable"},{"orgOrder":0,"company":"Yiviva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"CAR-T therapy","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Yiviva","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Yiviva \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Yiviva \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Yiviva

    Menu

    Yiviva

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Yiviva

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Yiviva

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : YIV-906,CAR-T therapy

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Preclinical Immunotherapy Research Featured in Poster Presentation at AACR 2022 Annual Meeting Highlights YIV-...

                            Details : YIV-906 (PHY906 or KD018), comprised of a proprietary cGMP botanical extract of four herbs inspired by Chinese medicine formulation, has been shown to prime and enhance immune function in tumor microenvironment, protect GIT and promote intestinal tissue ...

                            Brand Name : YIV-906

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 08, 2022

                            Lead Product(s) : YIV-906,CAR-T therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Yiviva

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Yiviva

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : YIV-906,Sorafenib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Yiviva Announces Dosing of First Patient in Phase 2b Study of First-Line YIV-906 Plus Sorafenib Combination Th...

                            Details : The randomized, placebo-controlled Phase 2b study of YIV-906 is evaluating efficacy, safety, and quality of life in patients with hepatitis B-positive HCC.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Not Applicable

                            April 06, 2020

                            Lead Product(s) : YIV-906,Sorafenib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth